MedTrace Logo

Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

NCT05349890 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2026-04-24

No results posted yet for this study

Summary

This is a phase I/Ib study of adoptively transferred T-cell receptor gene-engineered T cells (TCR-T) targeting tumor-specific antigens, with in vivo CD40 activation and PD-1 blockade, for patients with incurable cancers. The study design is a safety lead-in TCR-T with CD40/PD-1 (3+3), followed by Simon's Two-Stage expansion design, 80% power and 5% one-sided alpha: stage-one futility assessment at n = 10; stage-two assessment at n = 22, (accrual up to 24 to allow for potential study drop-out).

Conditions

  • Malignant Epithelial Neoplasms

Interventions

BIOLOGICAL

TCR-transduced T cells

TSA-reactive TCR-engineered T cells

DRUG

CDX-1140

Recombinant fully human IgG2κ monoclonal antibody

DRUG

Pembrolizumab

Humanized immunoglobulin G4 (IgG4) monoclonal antibody

Sponsors & Collaborators

  • Celldex Therapeutics

    collaborator INDUSTRY

  • Providence Cancer Center, Earle A. Chiles Research Institute

    collaborator OTHER

  • Providence Health & Services

    lead OTHER

Principal Investigators

  • Rom Leidner, MD · Providence Health & Services

  • Eric Tran, PhD · Providence Health & Services

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-03
Primary Completion
2027-04-15
Completion
2028-04-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05349890 on ClinicalTrials.gov